WTB
Resident
Sanofi Pasteur Receives Order
from French Government to Produce
Novel Influenza A(H1N1) Vaccine
Sanofi Pasteur to supply 28 million doses of A(H1N1) influenza vaccine
Option for an additional 28 million doses
Lyon, France - July 16, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group
(EURONEXT: SAN and NYSE: SNY), announced today it has received an order from the French Ministry
of Health to produce a vaccine against the novel A(H1N1) influenza virus.
This order from the French Ministry of Health provides for the initial supply of 28 million doses of the new
A(H1N1) influenza virus vaccine in final presentation, and includes an option for an additional 28 million
doses. This order was issued pursuant to an existing influenza pandemic vaccine supply agreement
between Sanofi Pasteur and the French government that allows the French Ministry of Health to
purchase vaccines for viruses identified by the World Heath Organization (WHO) as being involved in a
declared pandemic or having a pandemic potential.
The vaccine will be manufactured in Val de Reuil, France. Dosage requirements for the new vaccine are
yet to be determined and will be based on clinical trials outcomes. Final formulation, filling and distribution
of the vaccine should be determined in the coming months as the mass-production process will be
ongoing.
Sanofi Pasteur currently estimates it will have the first A(H1N1) vaccine doses ready for public health
officials within four to six months. This vaccine would help prevent the spread of the novel influenza
A(H1N1) virus strain. Its availability for administration would be subject to regulatory approval.
Sanofi Pasteur remains in continuous communication with the WHO and health authorities around the
world to help develop a tailored response to local public health needs.
Official Sanofi-Aventis press released
http://en.sanofi-aventis.com/binaries/20090716_ah1n1_en_tcm28-25686.pdf
from French Government to Produce
Novel Influenza A(H1N1) Vaccine
Sanofi Pasteur to supply 28 million doses of A(H1N1) influenza vaccine
Option for an additional 28 million doses
Lyon, France - July 16, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group
(EURONEXT: SAN and NYSE: SNY), announced today it has received an order from the French Ministry
of Health to produce a vaccine against the novel A(H1N1) influenza virus.
This order from the French Ministry of Health provides for the initial supply of 28 million doses of the new
A(H1N1) influenza virus vaccine in final presentation, and includes an option for an additional 28 million
doses. This order was issued pursuant to an existing influenza pandemic vaccine supply agreement
between Sanofi Pasteur and the French government that allows the French Ministry of Health to
purchase vaccines for viruses identified by the World Heath Organization (WHO) as being involved in a
declared pandemic or having a pandemic potential.
The vaccine will be manufactured in Val de Reuil, France. Dosage requirements for the new vaccine are
yet to be determined and will be based on clinical trials outcomes. Final formulation, filling and distribution
of the vaccine should be determined in the coming months as the mass-production process will be
ongoing.
Sanofi Pasteur currently estimates it will have the first A(H1N1) vaccine doses ready for public health
officials within four to six months. This vaccine would help prevent the spread of the novel influenza
A(H1N1) virus strain. Its availability for administration would be subject to regulatory approval.
Sanofi Pasteur remains in continuous communication with the WHO and health authorities around the
world to help develop a tailored response to local public health needs.
Official Sanofi-Aventis press released
http://en.sanofi-aventis.com/binaries/20090716_ah1n1_en_tcm28-25686.pdf